Duke Clinical Research Institute, Duke University Medical Center, Box 3850, 27710, Durham, NC, USA.
J Thromb Thrombolysis. 2010 Apr;29(3):368-77. doi: 10.1007/s11239-010-0439-7.
Acute ischemic stroke is the result of abrupt interruption of focal cerebral blood flow. The majority of ischemic strokes are caused by embolic or thrombotic arterial occlusions. Acute stroke management is complex, in part because of the varying etiologies of stroke and the very brief window of time for reperfusion therapy. Efforts to optimize stroke care have also encountered barriers including low public awareness of stroke symptoms. As initiatives move forward to improve stroke care worldwide, health care providers and institutions are being called onto deliver the most current evidence-based care. Updated versions of three major guidelines were published in 2008 by the American College of Chest Physicians, the American Heart Association, and the European Stroke Organization. This article presents a concise overview of current recommendations for the use of fibrinolytic therapy for acute ischemic stroke and antithrombotic therapy for secondary prevention. Future directions are also reviewed, with particular emphasis on improving therapeutic options early after stroke onset.
急性缺血性脑卒中是由于局灶性脑血流突然中断引起的。大多数缺血性脑卒中是由栓塞或血栓形成的动脉闭塞引起的。急性脑卒中的治疗非常复杂,部分原因是脑卒中的病因多种多样,再灌注治疗的时间窗口非常短暂。优化脑卒中治疗的努力也遇到了障碍,包括公众对脑卒中症状的认识程度较低。随着改善全球脑卒中护理的举措不断推进,医疗保健提供者和医疗机构被要求提供最当前的循证护理。2008 年,美国胸科医师学会、美国心脏协会和欧洲卒中组织发布了这三个主要指南的更新版本。本文简要概述了目前推荐用于急性缺血性脑卒中的纤维蛋白溶解治疗和二级预防的抗血栓治疗。还回顾了未来的发展方向,特别强调了在脑卒中发作后早期改善治疗选择。